Document Detail


A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature.
MedLine Citation:
PMID:  21357274     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The requirement of a metalloprotease, a disintegrin and metalloprotease 17 (ADAM17) for the growth of cultured vascular smooth muscle cells has been demonstrated in vitro. However, whether this metalloprotease is responsible for vascular remodeling in vivo remains unanswered. Rat carotid arteries were analyzed 2 weeks after a balloon angioplasty. The neointimal cells were strongly positive for ADAM17 immunostaining. Marked inhibition of intimal hyperplasia was observed in a dominant-negative ADAM17 adenovirus-treated carotid artery. Proliferating cell nuclear antigen-positive cells and phospho-epidermal growth factor receptor-positive cells in the neointima were reduced by dominant-negative ADAM17 as well. In contrast, the neointima formation, proliferating cell nuclear antigen-positive cells, and phospho-epidermal growth factor receptor-positive cells were markedly enhanced by wild-type ADAM17 adenovirus. In conclusion, ADAM17 activation is involved in epidermal growth factor receptor activation and subsequent neointimal hyperplasia after vascular injury. ADAM17 could be a novel therapeutic target for pathophysiological vascular remodeling.
Authors:
Akira Takaguri; Keita Kimura; Akinari Hinoki; Allison M Bourne; Michael V Autieri; Satoru Eguchi
Related Documents :
17060454 - Conditional deletion of the mouse klf4 gene results in corneal epithelial fragility, st...
19439204 - Towards understanding epithelial-mesenchymal transition: a proteomics perspective.
11447194 - Arginine-specific protease from porphyromonas gingivalis activates protease-activated r...
12912914 - Pak1 and pix regulate contact inhibition during epithelial wound healing.
8368314 - Decreased expression of protooncogenes c-fos, c-myc, and c-jun following polyamine depl...
23551454 - Safety, efficacy and pitfalls of fibrocyte application in the treatment of diabetic foo...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-02-28
Journal Detail:
Title:  Hypertension     Volume:  57     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-17     Completed Date:  2011-07-04     Revised Date:  2014-09-18    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  841-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ADAM Proteins / metabolism*
Angioplasty, Balloon
Animals
Carotid Arteries / metabolism,  pathology*
Carotid Artery Injuries / metabolism*,  pathology
Endothelium, Vascular / metabolism,  pathology
Hyperplasia / metabolism
Immunohistochemistry
Male
Muscle, Smooth, Vascular / cytology,  metabolism*,  pathology
Neointima / metabolism,  pathology*
Rats
Rats, Sprague-Dawley
Receptor, Epidermal Growth Factor / metabolism
Grant Support
ID/Acronym/Agency:
HL063810/HL/NHLBI NIH HHS; HL076770/HL/NHLBI NIH HHS; HL090885/HL/NHLBI NIH HHS; R01 HL076770/HL/NHLBI NIH HHS; R01 HL076770-06/HL/NHLBI NIH HHS; R01 HL076770-07/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 3.4.24.-/ADAM Proteins; EC 3.4.24.-/tumor necrosis factor-alpha convertase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of Cathepsin L as a Potential Sex-Specific Biomarker for Renal Damage.
Next Document:  Selective Endothelin-A Receptor Antagonism Reduces Proteinuria, Blood Pressure, and Arterial Stiffne...